February 2024

Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that it has launched Relugolix under the brand name, Rexigo™. This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India. Though Relugolix was available in developed countries since the last four years, patients in India did not have access to it. With this launch, Zydus brings both access to a critical therapy and also makes it affordable at a cost of Rs.

Pfizer and Glenmark Pharmaceuticals Ltd have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.